TGR5 in cholangiocytes

Current Opinion in Gastroenterology

Volumn 29, Issue 3, 2013, Pages 299-304

  Keitel, Verena ^a   Häussinger, Dieter ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

apoptosis; bile acids; choleresis; G protein coupled receptor; proliferation

Indexed keywords

BICARBONATE; CYCLIC AMP; FAS ANTIGEN; G PROTEIN COUPLED RECEPTOR; OBETICHOLIC ACID; TAUROCHOLIC ACID; TAUROLITHOCHOLIC ACID; TGR PROTEIN; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

BILE DUCT; BILE FLOW; CELL PROLIFERATION; GALLBLADDER; GENE LOCUS; HUMAN; NONHUMAN; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

BILE DUCTS; BILIARY TRACT DISEASES; CILIA; EPITHELIAL CELLS; HUMANS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84876290819     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32835f3f14     Document Type: Review

References (77)

1. Hofmann AF, Hagey LR. Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol Life Sci 2008; 65:2461-2483.
2. Keitel V, Kubitz R, Häussinger D. Endocrine and paracrine role of bile acids. World J Gastroenterol 2008; 14:5620-5629.
3. Thomas C, Pellicciari R, Pruzanski M, et al. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 2008; 7:678-693.
4. Houten SM, Watanabe M, Auwerx J. Endocrine functions of bile acids. EMBO J 2006; 25:1419-1425.
5. Keitel V, Häussinger D. Perspective: TGR5 (Gpbar-1) in liver physiology and disease. Clin Res Hepatol Gastroenterol 2012; 36:412-419.
6. Häussinger D, Reinehr R, Keitel V. Bile acid signaling in the liver and the biliary tree. In: Häussinger D, Keitel V, Kubitz R, editors. Hepatobiliary transport in health and disease. Berlin: DeGruyter Publishing; 2012. pp. 85-102.
7. Kalaany NY, Mangelsdorf DJ. LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu Rev Physiol 2006; 68:159-191.
8. Lefebvre P, Cariou B, Lien F, et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009; 89:147-191.
9. Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science 1999; 284:1362-1365.
10. Parks DJ, Blanchard SG, Bledsoe RK, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999; 284:1365-1368.
11. Staudinger JL, Goodwin B, Jones SA, et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci USA 2001; 98:3369-3374.
12. Xie W, Radominska-Pandya A, Shi Y, et al. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc Natl Acad Sci USA 2001; 98:3375-3380.
13. Gascon-Barre M, Demers C, Mirshahi A, et al. The normal liver harbors the vitamin D nuclear receptor in nonparenchymal and biliary epithelial cells. Hepatology 2003; 37:1034-1042.
14. Han S, Chiang JY. Mechanism of vitamin D receptor inhibition of cholesterol 7alpha-hydroxylase gene transcription in human hepatocytes. Drug Metab Dispos 2009; 37:469-478.
15. Makishima M, Lu TT, Xie W, et al. Vitamin D receptor as an intestinal bile acid sensor. Science 2002; 296:1313-1316.
16. Kawamata Y, Fujii R, Hosoya M, et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem 2003; 278:9435-9440.
17. Maruyama T, Miyamoto Y, Nakamura T, et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun 2002; 298:714-719.
18. Studer E, Zhou X, Zhao R, et al. Conjugated bile acids activate the sphingo-sine-1-phosphate receptor 2 in primary rodent hepatocytes. Hepatology 2012; 55:267-276.
19. Reinehr R, Becker S, Wettstein M, Häussinger D. Involvement of the Src family kinase yes in bile salt-induced apoptosis. Gastroenterology 2004; 127:1540-1557.
20. Reinehr R, Becker S, Keitel V, et al. Bile salt-induced apoptosis involves NADPH oxidase isoform activation. Gastroenterology 2005; 129:2009-2031.
21. Becker S, Reinehr R, Grether-Beck S, et al. Hydrophobic bile salts trigger ceramide formation through endosomal acidification. Biol Chem 2007; 388:185-196.
22. Häussinger D, Kubitz R, Reinehr R, et al. Molecular aspects of medicine: from experimental to clinical hepatology. Mol Aspects Med 2004; 25:221-360.
23. Häussinger D, Kurz AK, Wettstein M, et al. Involvement of integrins and Src in tauroursodeoxycholate-induced and swelling-induced choleresis. Gastroen-terology 2003; 124:1476-1487.
24. Graf D, Kurz AK, Fischer R, et al. Taurolithocholic acid-3 sulfate induces CD95 trafficking and apoptosis in a c-Jun N-terminal kinase-dependent manner. Gastroenterology 2002; 122:1411-1427.
25. Kurz AK, Graf D, Schmitt M, et al. Tauroursodeoxycholate-induced choleresis involves p38(MAPK) activation and translocation of the bile salt export pump in rats. Gastroenterology 2001; 121:407-419.
26. Schliess F, Kurz AK, vom Dahl S, Häussinger D. Mitogen-activated protein kinases mediate the stimulation of bile acid secretion by tauroursodeoxycho-late in rat liver. Gastroenterology 1997; 113:1306-1314.
27. Sato H, Macchiarulo A, Thomas C, et al. Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies. J Med Chem 2008; 51:1831-1841.
28. Keitel V, Görg B, Bidmon HJ, et al. The bile acid receptor TGR5 (Gpbar-1) acts as a neurosteroid receptor in brain. Glia 2010; 58:1794-1805.
29. Maruyama T, Tanaka K, Suzuki J, et al. Targeted disruption of G protein-coupled bile acid receptor 1 (Gpbar1/M-Bar) in mice. J Endocrinol 2006; 191:197-205.
30. Vassileva G, Golovko A, Markowitz L, et al. Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation. Biochem J 2006; 398:423-430.
31. Cipriani S, Mencarelli A, Chini MG, et al. The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. PLoS One 2011; 6:e25637.
32. Poole DP, Godfrey C, Cattaruzza F, et al. Expression and function of the bile acid receptor GpBAR1 (TGR5) in the murine enteric nervous system. Neurogastroenterol Motil 2010; 22:814-825.
33. Thomas C, Gioiello A, Noriega L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 2009; 10:167-177.
34. Alemi F, Poole DP, Chiu J, et al. The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice. Gastroenterology 2013; 144:145-154.
35. Keitel V, Reinehr R, Gatsios P, et al. The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. Hepatology 2007; 45:695-704.
36. Keitel V, Donner M, Winandy S, et al. Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem Biophys Res Commun 2008; 372:78-84.
37. Keitel V, Cupisti K, Ullmer C, et al. The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. Hepatology 2009; 50:861-870.
38. Keitel V, Ullmer C, Häussinger D. The membrane-bound bile acid receptor TGR5 (Gpbar-1) is localized in the primary cilium of cholangiocytes. Biol Chem 2010; 391:785-789.
39. Keitel V, Häussinger D. TGR5 in the biliary tree. Dig Dis 2011; 29:45-47.
40. Lavoie B, Balemba OB, Godfrey C, et al. Hydrophobic bile salts inhibit gallbladder smooth muscle function via stimulation of GPBAR1 receptors and activation of KATP channels. J Physiol 2010; 588:3295-3305.
41. Li T, Holmstrom SR, Kir S, et al. The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling. Mol Endocrinol 2011; 25:1066-1071.
42. Angelin B, Bjorkhem I, Einarsson K, Ewerth S. Hepatic uptake of bile acids in man. Fasting and postprandial concentrations of individual bile acids in portal venous and systemic blood serum. J Clin Invest 1982; 70:724-731.
43. Einarsson K, Alvelius G, Hillebrant CG, et al. Concentration of unsulfated lithocholic acid in portal and systemic venous plasma: evidence that litho-cholic acid does not down regulate the hepatic cholesterol 7 alpha-hydro-xylase activity in gallstone patients. Biochim Biophys Acta 1996; 1317:19-26.
44. Fukushima K, Ichimiya H, Higashijima H, et al. Regulation of bile acid synthesis in the rat: relationship between hepatic cholesterol 7 alpha-hydroxylase activity and portal bile acids. J Lipid Res 1995; 36:315-321.
45. Pols TW, Nomura M, Harach T, et al. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab 2011; 14:747-757.
46. Wang YD, Chen WD, Yu D, et al. The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light-chain enhancer of activated B cells (NF-kappaB) in mice. Hepatology 2011; 54:1421-1432.
47. Xia X, Francis H, Glaser S, et al. Bile acid interactions with cholangiocytes. World J Gastroenterol 2006; 12:3553-3563.
48. Pols TW, Noriega LG, Nomura M, et al. The bile acid membrane receptor TGR5as an emerging target in metabolism and inflammation. JHepatol 2011; 54:1263-1272.
49. Beuers U, Hohenester S, de Buy Wenniger LJ, et al. The biliary HCO(3)(-) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. Hepatology 2010; 52:1489-1496.
50. - umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. Hepatology 2012; 55:173-183.
51. Alpini G, Glaser S, Baiocchi L, et al. Secretin activation of the apical Na-dependent bile acid transporter is associated with cholehepatic shunting in rats. Hepatology 2005; 41:1037-1045.
52. Howard M, Jiang X, Stolz DB, et al. Forskolin-induced apical membrane insertion of virally expressed, epitope-tagged CFTR in polarized MDCK cells. Am J Physiol Cell Physiol 2000; 279:C375-C382.
53. Pellicciari R, Gioiello A, Macchiarulo A, et al. Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity. J Med Chem 2009; 52:7958-7961.
54. Alpini G, Glaser S, Robertson W, et al. Bile acids stimulate proliferative and secretory events in large but not small cholangiocytes. Am J Physiol 1997; 273:G518-G529.
55. Alpini G, Glaser SS, Ueno Y, et al. Bile acid feeding induces cholangiocyte proliferation and secretion: evidence for bile acid-regulated ductal secretion. Gastroenterology 1999; 116:179-186.
56. Reinehr R, Häussinger D. Inhibition of bile salt-induced apoptosis by cyclic AMP involves serine/threonine phosphorylation of CD95. Gastroenterology 2004; 126:249-262.
57. Keitel V, Reinehr R, Reich M, et al. The membrane-bound bile acid receptor TGR5 (Gpbar-1) is highly expressed in intrahepatic cholangiocarcinoma. Hepatology 2011; 54. [abstract].
58. Chen WD, Yu D, Forman BM, et al. The deficiency of G-protein-coupled bile acid receptor Gpbar1 (TGR5) enhances chemically-induced liver carcino-genesis. Hepatology 2013; 57:656-666.
59. Vassileva G, Hu W, Hoos L, et al. Gender-dependent effect of Gpbar1 genetic deletion on the metabolic profiles of diet-induced obese mice. J Endocrinol 2010; 205:225-232.
60. Franke A, Balschun T, Karlsen TH, et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet 2008; 40:1319-1323.
61. Karlsen TH, Franke A, Melum E, et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology 2010; 138:1102-1111.
62. Hov JR, Keitel V, Laerdahl JK, et al. Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PLoS One 2010; 5:e12403.
63. Van Nieuwkerk CM, Elferink RP, Groen AK, et al. Effects of ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene. Gastroenterology 1996; 111:165-171.
64. -/-) mouse cholangiopathy model by promoting biliary HCO output. Hepatology 2011; 54:1303-1312.
65. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005; 353:1261-1273.
66. Poupon R. Primary biliary cirrhosis: a 2010 update. J Hepatol 2010; 52:745-758.
67. Medina JF, Martinez A, Vazquez JJ, Prieto J. Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis. Hepatol-ogy 1997; 25:12-17.
68. Prieto J, Garcia N, Marti-Climent JM, et al. Assessment of biliary bicarbonate secretion in humans by positron emission tomography. Gastroenterology 1999; 117:167-172.
69. Medina JF. Role ofthe anion exchanger2 inthe pathogenesis and treatmentof primary biliary cirrhosis. Dig Dis 2011; 29:103-112.
70. Hirschfield G, Kowdley K, Mason A, et al. 952 Long-term (LT) therapy of a farnesoid X receptor (FXR) agonist obeticholic acid (OCA) maintains biochemical response in primary biliary cirrhosis (PBC). J Hepatol 2012; 56:S372. [abstract].
71. Mason A, Luketic V, Lindor K, et al. 2 Farnesoid-X receptor agonists: a new class of drugs for the treatment of PBC? An international study evaluating the addition of INT-747 to ursodeoxycholic acid. J Hepatol 2010; 52:S1-S2. [abstract].
72. Poupon R. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. Clin Res Hepatol Gastroenterol 2012; 36 (Suppl. 1):S3-S12; doi: 10.1016/S2210-7401:-3.
73. Rizzo G, Passeri D, De FF, et al. Functional characterization of the semisyn-thetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist. Mol Pharmacol 2010; 78:617-630.
74. Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 2008; 48:308-321.
75. Sirica AE. Cholangiocarcinoma: molecular targeting strategies for chemo-prevention and therapy. Hepatology 2005; 41:5-15.
76. Hong J, Behar J, Wands J, et al. Role of a novel bile acid receptor TGR5 in the development of oesophageal adenocarcinoma. Gut 2010; 59:170-180.
77. Yasuda H, Hirata S, Inoue K, et al. Involvement of membrane-type bile acid receptor M-BAR/TGR5 in bile acid-induced activation of epidermal growth factor receptor and mitogen-activated protein kinases ingastriccarcinomacells. Biochem Biophys Res Commun 2007;354:154-159.